FTA Therapeutics

FTA Therapeutics LLC was a biopharmaceutical company focused on the development of free-ion based topical drug delivery systems and surface applications designed to prevent and treat infections caused by drug-resistant microorganisms. The company's primary technology utilized silver dihydrogen citrate (SDC), a proprietary antimicrobial agent licensed from PURE Bioscience, to target conditions such as MRSA, chronic wounds, and medical biofilms. Active in the late 2000s, FTA Therapeutics established a significant partnership with the Cleveland Clinic Foundation, which took an equity stake in the company to support clinical development. Despite its innovative approach to antimicrobial therapy and dermatology, the company appears to have ceased operations after 2010.